Journal of Clinical & Experimental Neuroimmunology

Commentary Open Access

Clinical Course and Management of Neurologic Adverse Events Linked to Immune Checkpoint Therapy

Ester Inaebnit*

Department of Psychiatry, University College London, London, United Kingdom

Abstract

Neurologic adverse events (NAEs) associated with immune checkpoint inhibitors (ICIs) have emerged as significant complications in cancer immunotherapy. While ICIs have revolutionized the treatment of various malignancies, their role in eliciting immune-related adverse events, particularly affecting the nervous system, presents challenges in clinical management. NAEs can manifest as peripheral neuropathies, encephalitis, myasthenia gravis, and other neurologic disorders, often occurring weeks to months after treatment initiation. Early recognition and prompt intervention are crucial for mitigating potential long-term morbidity. This review examines the clinical presentation, incidence, risk factors, diagnostic evaluation, and management strategies for neurologic adverse events linked to ICIs. Emphasizing a multidisciplinary approach, we highlight the importance of tailored treatment plans that balance the therapeutic benefits of ICIs with the risks of neurologic complications. As research progresses, a deeper understanding of these events will enhance patient care and outcomes in the context of cancer immunotherapy [1].

Introduction

The advent of immune checkpoint therapy has significantly improved survival rates in various malignancies, including melanoma, lung cancer, and renal cell carcinoma. Despite their therapeutic benefits, ICIs can induce a spectrum of immune-related adverse events (irAEs), particularly affecting the neurologic system. Understanding the clinical course and management of these events is essential for optimizing patient outcomes.

Neurologic adverse events: an overview

Neurologic irAEs can manifest in several forms, including:

- **Neuropathy**: Peripheral neuropathies, such as Guillain-Barré syndrome, may occur, presenting with weakness and sensory disturbances.
- **Encephalitis**: Patients may develop encephalitis characterized by altered mental status, seizures, and neurological deficits.
- **Meningitis**: Aseptic meningitis can arise, often presenting with headache, fever, and neck stiffness.
- **Myasthenia gravis**: This autoimmune disorder may be exacerbated or triggered by ICIs, leading to muscle weakness and fatigue.
- **Cerebrovascular events**: Thromboembolic events, including stroke, have been reported in association with ICI therapy [2].

Incidence and risk factors

The incidence of neurologic irAEs varies, with some studies suggesting rates between 1% and 7%. Risk factors may include:

- Pre-existing autoimmune conditions
- Combination therapy with other immunotherapeutics
- Specific ICI classes (e.g., PD-1/PD-L1 vs. CTLA-4 inhibitors)

Clinical course

The clinical course of neurologic adverse events can be variable, with onset often occurring weeks to months after initiating therapy. Symptoms may evolve rapidly, necessitating prompt assessment and intervention. Early identification is crucial, as neurologic complications can lead to significant morbidity and impact cancer treatment continuity.

Diagnostic evaluation

A comprehensive diagnostic approach is essential. Recommended evaluations include:

- **Neurological Examination**: Detailed assessment of motor and sensory function.
- **Neuroimaging**: MRI and CT scans can help rule out structural causes.
- **Lumbar Puncture**: Cerebrospinal fluid analysis is vital for diagnosing encephalitis or meningitis.
- **Electrophysiological Studies**: These can confirm neuropathies and myasthenia gravis.

Management strategies

Management of neurologic irAEs typically involves a multidisciplinary approach:

1. Corticosteroids

High-dose corticosteroids are the first-line treatment for moderate to severe neurologic irAEs. The dosing regimen may start at 1-2 mg/kg/day, tapering based on clinical response [3-7].

2. Immunosuppressive agents

***Corresponding author:** Ester Inaebnit, Department of Psychiatry, University College London, London, United Kingdom, E-mail: Inaebnit@gmail.com

Received: 01-May-2024, Manuscript No. jceni-24-148920; **Editor assigned:** 03-May-2024, Pre QC-No. jceni-24-148920 (PQ); **Reviewed:** 17-May-2024, QC No: jceni-24-148920; **Revised:** 24-May-2024, Manuscript No. jceni-24-148920 (R); **Published:** 31-May-2024, DOI: 10.4172/jceni.1000241

Citation: Ester I (2024) Clinical Course and Management of Neurologic Adverse Events Linked to Immune Checkpoint Therapy. J Clin Exp Neuroimmunol, 9: 241.

For refractory cases, additional immunosuppressive therapies may be necessary. Options include:

- **Intravenous Immunoglobulin (IVIG)**
- **Plasmapheresis**
- **Other immunosuppressants** (e.g., mycophenolate mofetil, rituximab)

3. Supportive care

Symptomatic management is crucial, particularly for neuropathic pain and muscle weakness. Referral to neurology and rehabilitation services may enhance recovery.

Prognosis

The prognosis for patients experiencing neurologic irAEs varies widely based on the severity of symptoms and the timeliness of intervention. Early recognition and appropriate management can lead to favorable outcomes, allowing for the continuation of oncologic therapy when possible.

Conclusion

Neurologic adverse events associated with immune checkpoint therapy represent a complex and significant challenge in the management of patients undergoing cancer treatment. These events can vary widely in presentation and severity, necessitating prompt recognition and intervention to minimize morbidity. Early diagnosis, utilizing a multidisciplinary approach, is crucial for effective management, often involving corticosteroids and other immunosuppressive therapies. As our understanding of the mechanisms underlying these neurologic complications continues to evolve, ongoing research is essential to refine management strategies and improve patient outcomes. Ultimately, balancing the benefits of immune checkpoint inhibitors with the risks of neurologic irAEs is vital in optimizing cancer care and enhancing the quality of life for patients. Continued education and awareness among healthcare providers will be key in addressing these adverse events effectively.

References

1. Hattwick MAW, Weiss TT, Stechschulte CJ (1972) Recovery from rabies. Annals Internal Med 76: 931-942.
2. Porras C, Barboza JJ, Fuenzalida E, Adaros HL, Oviedo AM, et al. (1976) Recovery from rabies in man. Ann Intern Med 85: 44-48.
3. Tillotson JR, Axelrod D, Lyman DO (1977) Rabies in a laboratory worker - New York. Morbidity Mortality Weekly Rep 26: 1830-1834.
4. Alvarez L, Fajardo R, Lopez E, Pedroza R, Hemachudha T, et al. (1994) Partial recovery from rabies in a nine-year-old boy. Pediatric Infect Dis J 13: 1154-1155.
5. Madhusudana SN, Nagaraj D, Uday M, Ratnavalli E, Verendra Kumar M (2002) Partial recovery from rabies in a six-year old girl. Int J Infect Dis 6: 85-86.
6. Willoughby RE, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, et al. (2005) Survival after treatment of rabies with induction of coma. N Engl J Med 352: 2508-2514.
7. Weyer J, Msimang-Dermaux V, Paweska JT, Roux KL, Govender P, et al. (2016) A case of human survival of rabies, South Africa. S Afr J Infect Dis 31: 66-68.